Content area

|
|

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Kutant melanom. (Foto: Pia Sjøgren).
Forfatter(e)
Louise Elkjær Fløe1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V01160070
Reference: 
Ugeskr Læger 2016;178:V01160070
Blad nummer: 
Sidetal: 
2-5
Immune checkpoint antibodies increase survival in patients with metastatic melanoma
The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Tom Buur | 20/07
3 kommentarer
af Niels Albert Graudal | 16/07
4 kommentarer
af Christian F. Asmussen | 15/07
1 Kommentar
af Christian F. Asmussen | 15/07
1 Kommentar
af Jørgen Alving | 12/07
2 kommentarer
af Mogens Holbech Dahl | 10/07
3 kommentarer
af Elisabeth Sirkka Augustina Bright | 06/07
2 kommentarer
af Lars Høj | 06/07
1 Kommentar
af Christian E. H. R. Freitag | 04/07
8 kommentarer